Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

SIMPLE SUMMARY: Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to HER-2 therapy resistance and may be predictive of...

Descripción completa

Detalles Bibliográficos
Autores principales: Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999809/
https://www.ncbi.nlm.nih.gov/pubmed/33799597
http://dx.doi.org/10.3390/cancers13061225

Ejemplares similares

Ejemplares similares